Destiny Pharma’s potentially revolutionary product ‘XF-73’ progresses into next stage study
The dermal product aims to radically change wound care for cases such as diabetic foot ulcers
Destiny Pharma is developing the novel formulation of XF-73 Dermal for the prevention of infections associated with open wounds and broken skin including diabetic foot ulcers (DFUs) – up to 25% of US diabetic patients may suffer from DFUs in their lifetime and c. 13% have active ulcers. The XF-73 Dermal product is planned to be a fast, cost-effective dermal treatment that kills all relevant bacteria quickly, helping the wound heal and combatting the threat of Antimicrobial Resistance (AMR) through its novel, patented action.
Destiny Pharma will continue to work with NIAID to complete this preclinical safety package which will support future clinical development of XF-73 Dermal in serious wound infections. The study is planned to complete in Q2 2023 and should then be ready to move into clinical trials.
Neil Clark, CEO of Destiny Pharma, said: “We are very pleased with the continuing progress of our novel XF-73 Dermal infection programme which is targeted at meeting a clear clinical need driven by the increasing incidence of diabetes across the world. There are 29 million people diagnosed in the United States alone who are at risk of developing diabetic foot ulcer infections and peak product sales could reach half a billion US dollars. The start of this second preclinical study means that this programme is well placed to deliver a second clinical candidate in 2023 from our XF platform following the excellent Phase 2 clinical results generated for the XF-73 Nasal gel for the prevention of post-surgical infections caused by Staphylococcal aureus.”